Blood-stable, cholesterol-free liposomes

• US 5,043,164 A
• Filed: 01/17/1989
• Issued: 08/27/1991
• Est. Priority Date: 01/17/1989
• Status: Expired due to Fees

• Current Assignee: BioWhittaker, Inc. (Lonza Group AG)
• Original Assignee: The University Of Tennessee Research Corporation (University of Tennessee)
• Inventors: Liu, Dexi, Huang, Leaf
• Primary Examiner(s): Lovering, Richard D.
• Assistant Examiner(s): Covert, John M.
• Application Number:
  US07/298,452
• Time in Patent Office: 952 Days
• Field of Search: 424/450, 424/423, 436/829, 264/4.1, 264/4.3, 264/4.6, 428/402.21, 428/402.22, 514/970, 514/971
• US Class Current: 424/423
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1275 Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
• CPC Class Codes: Y10S 436/829 Liposomes, e.g. encapsulation
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]

Abstract

Small unilamellar liposomes (d<600 nm) comprising an unsaturated phosphatidylethanolamine (PE) such as dioleoyl PE (DOPE) and a fatty acid such as oleic acid (OA) are stabilized by adding to a freshly prepared liposome suspension, an amphipile which has a high tendency to form micelles. Examples are shown for the following micelle-forming amphiphiles: lysophospholipide, gangliosides (GM₁ and GTlb), sulfatide, synthetic glycopholipids such as sialo-lactosyl phosphatidylethanolamine, liopohilic drugs such as cytosine arabinoside diphosphate diacyglycerol, and proteins such as cytochrome b₅, human high density lipoprotein (HDL), and human glycophorin A. The stabilized liposomes are resistant to the lytic action of albumin, the major blood component which causes the lysis of this type of liposome. Prior to the present invention, liposomes comprising PE and OA were typically stabilized by the incorporation of cholesterol.

Claims

1. A method of stabilizing freshly prepared, small, unilamellar liposomes in blood or body fluids, said liposomes consisting essentially of an unsaturated phosphatidylethanolamine and a fatty acid as the major components of the liposome preparation, which comprises adding a blood or body fluid stabilizing amount of a micelle-forming amphiphile to a suspension of said liposomes.

2. The method of claim 1, wherein the unsaturated phosphatidylethanolamine in the liposome preparation is dioleoyl phosphatidylethanolamine.

3. The method of claim 2, wherein the fatty acid in the liposome preparation is oleic acid.

4. The method of claim 3, wherein the ratio of dioleoyl phosphatidylethanolamine to oleic acid in the liposome preparation is from about 10:

1 to 1;

10.

5. The method of claim 3, wherein the ratio of dioleoyl phosphatidylethanolamine to oleic acid in the liposome preparation is from about 5:

1 to 1;

5.

6. The method of claim 3, wherein the ratio of dioleoyl phosphatidylethanolamine to oleic acid in the liposome preparation is from about 2:

1 to 1;

2.

7. The method of claim 1, wherein the micelle-forming amphiphile is selected from the group consisting of micelle-forming lysophospholipids, gangliosides, sulfatide, synthetic glycophospholipids, lipophilic drugs, and amphipathic proteins

8. The method of claim 7, wherein the ganglioside is selected from the group consisting of GM₁ and GTlb.

9. The method of claim 7, wherein the synthetic glycophospholipid is sialolactosylphosphatidylethanolamine.

10. The method of claim 7, wherein the lipophilic drug is cytosine arabinoside diphosphate diacyglycerol.

11. The method of claim 7, wherein the amphipathic proteins are selected from the group consisting of cytochrome b₅, human high density lipoprotein (HDL), human low density lipoprotein (LDL), human very low density lipoprotein (VLDL), and human glycophorin A.

19. Blood-stable, cholesterol-free liposomes prepared by the method of claim 1.

12. A method of stabilizing freshly prepared, small, unilamellar liposomes in blood or other body fluids, said liposomes consisting essentially of an unsaturated phosphatidylethanolamine and a fatty acid as the major components of the liposome preparation, which comprises mixing said liposomes with a stabilizing amount of human plasma, serum or whole blood.

13. The method of claim 12, wherein the unsaturated phosphatidylethanolamine in the liposome preparation is dioleoyl phosphatidylethanolamine.

14. The method of claim 13, wherein the fatty acid in the liposome preparation is oleic acid.

15. The method of claim 14, wherein the ratio of dioleoyl phosphatidylethanolamine to oleic acid in the liposome preparation is from about 10:

1 to 1;

10.

16. The method of claim 14, wherein the ratio of dioleoyl phosphatidylethanolamine to oleic acid in the liposome preparation is from about 5:

1 to 1;

5.

17. The method of claim 14, wherein the ratio of dioleoyl phosphatidylethanolamine to oleic acid in the liposome preparation is from about 2:

1 to 1;

2.

18. The method of claim 12, which further comprises purifying the stabilized liposomes by removing them from contact with said human plasma, serum, or whole blood.

20. Blood-stable, cholesterol-free liposomes prepared by the method of claim 12.

21. A method of delivering one or more drugs to a mammalian patient so as to greatly reduce the chance of cross-contamination and cross-reaction of the blood of said patient with blood products from other sources, said method comprising the steps of:

(a) freshly preparing small unilamellar liposomes consisting essentially of (2;

1) DOPE;

OA, said liposomes encapsulating the one or more drugs to be delivered to said patient;

(b) stabilizing the freshly prepared liposomes by mixing said liposomes with a stabilizing amount of the patient'"'"'s own blood, serum or plasma; and

(c) injecting into the patient, an effective amount of the drug containing stabilized liposomes.

22. The method of claim 21, wherein the stabilizing amount of the patient'"'"'blood, serum, or plasma is about 50% by weight.